Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant COVID-19 (XBB) trimer protein vaccine
- Development stage
- Phase 3
- Lead developer
- WestVac Biopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
A recombinant COVID-19 (XBB) trimer protein vaccine is a subunit, protein-based vaccine designed to protect against SARS-CoV‑2 Omicron subvariants, particularly those in the XBB lineage such as XBB.1.5 and its descendants. The antigen is a self-assembled spike-protein trimer, produced using an insect cell expression system, and formulated with an oil-in-water emulsion adjuvant to enhance immunogenicity[6][1]. The mechanism of action involves inducing neutralizing antibodies and T-cell responses targeting the spike receptor-binding domain of SARS-CoV‑2 Omicron variants[6][3][1]. Developed primarily by WestVac Biopharma, this platform has demonstrated robust neutralization against current circulating Omicron sublineages including JN.1, KP.2, and KP.3[6][1]. It has received emergency use authorization in China for prevention of COVID‑19 caused by these variants.
- Brand names
- Coviccine Trivalent XBB.1.5
- Other names
- recombinant COVID-19 (XBB) trimer protein vaccineXBB.1.5-recombinant COVID-19 trivalent protein vaccineRecombinant XBB booster
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike glycoprotein receptor-binding domain, Omicron XBB lineageOmicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)
Beyond the preview
Go deeper on recombinant COVID-19 (XBB) trimer protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant COVID-19 (XBB) trimer protein vaccine.